UAE Cancer Immunotherapy Market Analysis

UAE Cancer Immunotherapy Market Analysis


$ 3999

UAE's cancer immunotherapy market is expected to witness growth from $563 Mn in 2022 to $1,049 Mn in 2030 with a CAGR of 8.1% for the forecasted year 2022-30. The increasing incidence of cancer in the UAE along with favorable government initiatives to promote the use of immunotherapy treatment in the UAE are responsible for the growth of the market. The UAE cancer immunotherapy market is segmented by type, application, and end user. Lamba, Neopharma, and Bayer are the major players in the UAE cancer immunotherapy market.

ID: IN10AEPH032 CATEGORY: Pharmaceuticals GEOGRAPHY: UAE AUTHOR: Dr. Parul Choudhary

Buy Now

UAE Cancer Immunotherapy Market Executive Analysis

UAE's cancer immunotherapy market is expected to witness growth from $563 Mn in 2022 to $1,049 Mn in 2030 with a CAGR of 8.1% for the forecasted year 2022-30. The future holds growth for Dubai's healthcare industry. According to the Dubai Chamber of Commerce and Industry, revenue generated within the whole UAE healthcare sector is anticipated to increase by 7.5% annually to reach $10.7 Bn by 2025. Meanwhile, it is anticipated that healthcare spending will increase to 4.6% of GDP by 2026 and 5.1% of GDP by 2029. With increased government initiatives, the UAE healthcare business is expanding at an astounding rate. Additionally, the UAE government is significantly enhancing and extending its healthcare system in order to create a powerful, top-notch healthcare infrastructure. To improve the current infrastructure and match the caliber of services provided in other nations, the government is also promoting private sector participation.

WHO estimates that by 2030, there may be up to 961,098 more cancer cases than there were in 2012 (555,318). The high incidence of breast, lung, thyroid, cervical, and colorectal cancer in the UAE is a result of an unhealthy lifestyle and insufficient medical care.

Cancer immunotherapy is a new subject in the UAE that is attracting more and more interest from patients and medical professionals. Utilizing the body's natural immune system to combat cancer cells is how immunotherapy treatment functions. Immune checkpoint inhibitors, CAR T-cell therapy, and cancer vaccines are just a few of the cancer immunotherapy therapies offered in the UAE. To provide patients with the best results, these treatments are frequently applied in conjunction with conventional cancer therapies like chemotherapy or radiation therapy. The Abu Dhabi Stem Cell Center and the Dubai Biotechnology and Research Park are two examples of the UAE government's investments in cancer research and treatment. These programs give patients access to the most recent therapies and technologies while also advancing the field of cancer immunotherapy in the UAE.

UAE Cancer Immunotherapy Market Analysis

Market Dynamics

Market Growth Drivers

Incidences of cancer have been rising in the UAE in recent years, and lifestyle choices including smoking, eating poorly, and not exercising have all contributed to the rise. The market for cancer immunotherapy treatments is significantly expanded as a result of the rising incidence of cancer. The government of the UAE has made significant investments in the growth of its healthcare infrastructure and services, contributing to the country's high level of healthcare spending. This investment is anticipated to aid in the UAE cancer immunotherapy market expansion. Through programs like the Dubai Future Accelerators program, which seeks to unite established and startup healthcare businesses to create fresh healthcare solutions, the UAE government has been promoting healthcare innovation. The development of novel cancer immunotherapy therapies is anticipated to be accelerated by this financing.

Market Restraints

Cancer immunotherapy medications are expensive, and some patients do not have insurance coverage. There is a shortage of qualified medical personnel who can provide immunotherapy. delays in the approval of drugs due to regulatory issues. Limited knowledge of the possible adverse effects and mechanisms of action of immunotherapeutic medicines. These factors limit the expansion of the UAE cancer immunotherapy market.

Competitive Landscape

Key Players

  • NewBridge Pharmaceuticals (ARE)
  • Pharmax (ARE)
  • Shalina Healthcare (ARE)
  • Lamba (ARE)
  • Neopharma (ARE)
  • Bayer
  • Bristol-Myers Squibb
  • Eli Lily
  • F. Hoffmann-La Roche
  • Pfizer
  • Johnson & Johnson
  • Merck

Notable Deals

April 2023- The Ministry of Health and Prevention in the UAE has approved the use of Merck Sharp and Dohme's (MSD) immunotherapy for a novel indication that will provide patients with triple-negative breast cancer (TNBC) hope. The introduction of this new medication will give patients with TNBC newfound optimism. Now, they can have this immunotherapy from both public and private facilities. In addition, he confirmed that when using the medicine instead of simply chemotherapy, the reoccurrence rate of TNBC was lower.

Healthcare Policies and Regulatory Landscape

The "Thiqa" program, which is the country's national health insurance policy, covers cancer treatment in the UAE. All UAE citizens and foreign immigrants are given basic health insurance coverage through this scheme. Chemotherapy, radiation therapy, and surgery are all covered under the Thiqa program for cancer treatment. The type of cancer and the stage of the disease, however, can affect the scope of coverage. Patients may need to pay out-of-pocket for some treatments, like immunotherapy and targeted medicines, or look for coverage through private health insurance policies since some treatments might not be covered by the Thiqa program. The UAE government has put in place a fee-for-service reimbursement approach for healthcare providers. This implies that, as opposed to a capitation model that pays a fixed sum per patient, healthcare providers are paid according to the services they render. This paradigm may encourage healthcare providers to offer additional services, such as cancer treatments, but it may also increase patient healthcare expenses.

1. Executive Summary
1.1 Disease Overview
1.2 Global Scenario
1.3 Country Overview
1.4 Healthcare Scenario in Country
1.5 Patient Journey
1.6 Health Insurance Coverage in Country
1.7 Active Pharmaceutical Ingredient (API)
1.8 Recent Developments in the Country

2. Market Size and Forecasting
2.1 Epidemiology of Disease
2.2 Market Size (With Excel & Methodology)
2.3 Market Segmentation (Check all Segments in Segmentation Section)

3. Market Dynamics
3.1 Market Drivers
3.2 Market Restraints

4. Competitive Landscape
4.1 Major Market Share

4.2 Key Company Profile (Check all Companies in the Summary Section)

4.2.1 Company
4.2.1.1 Overview
4.2.1.2 Product Applications and Services
4.2.1.3 Recent Developments
4.2.1.4 Partnerships Ecosystem
4.2.1.5 Financials (Based on Availability)

5. Reimbursement Scenario
5.1 Reimbursement Regulation
5.2 Reimbursement Process for Diagnosis
5.3 Reimbursement Process for Treatment

6. Methodology and Scope

Cancer Immunotherapy Segmentation

By Type (Revenue, USD Billion):

  • Monoclonal Antibodies
  • Cancer Vaccines
  • Checkpoint Inhibitors
  • Immunomodulators
  • PD-1/PD-L1
  • CTLA-4

By Application (Revenue, USD Billion):

  • Lung Cancer
  • Breast Cancer
  • Head and Neck Cancer
  • Prostate Cancer
  • Colorectal Cancer
  • Melanoma
  • Others

By End User (Revenue, USD Billion):

  • Hospitals
  • Clinics
  • Ambulatory Surgical Centers (ASCs)
  • Cancer Research Centers

Insights10 will provide you with the reports within 10 key parameters which are:

  1. Market Overview
  2. Market Growth Drivers & Restraints
  3. Epidemiology of Disease Type
  4. Market Segmentation
  5. Market Share
  6. Competitive Landscape
  7. Key Company Profiles
  8. Healthcare Policies & Regulatory Framework
  9. Reimbursement Scenario
  10. Factors Driving Future Growth

Based on our many years of experience, we believe that these are the parameters that are critical to decision-making for business stakeholders. Our focused approach to developing reports focused on 10 key parameters, enabled us to arrive at the name “Insights10”.

 

Stage I: Market Data Collection

Primary Interviews: We have developed a network of experts, freelancers, and researchers across countries through which we engage with local experts to gather key data points and assumptions about each market. We also engage regularly with some of the best market research agencies such as Atheneum, GuidePoint, GLG, etc. to conduct surveys and interviews, and build intelligence. We have language translators as a part of our team, who between them can cover 30+ languages allowing us to extract better local insights.

Secondary Data Collection: We have developed strong expertise and experience in secondary data collection methods for developing unique data sets and research material. We gather data from multiple reliable sources to maintain a high level of accuracy and consistency. The market data is analyzed and forecasted using appropriate statistical and coherent models. The report offers an overall analysis of the market size, growth, and market share as well as a segment-level analysis of the specific market. Our report includes precise, to-the-point information related to the overall market, competition, growth drivers, challenges, regulatory updates, and competition.

Data Sources: We have access to multiple highly reliable free and subscription data sources. We have many years of experience to understand which sources are more dependable for what and which to prefer for the reliable and latest information. The key sources of information include the following, but are not limited to:

 

 

Stage II: Market Data Analysis and Statistical Model

Market Trends: We generally look at macro parameters and micro indicators. The macro parameters include changes in government policies, demand and supply of the market, government intervention programs, and major market share. The micro indicators are GDP growth, market size, market volume, etc. We also understand nuances specific to each country like the US, Canada, India, Germany, etc., and have worked across 60+ countries and hence not only understand global trends but how these differ by country, how payment models, market structure, cultural parameters, etc. differ in each country.

Market Sizing and Analysis: Our expert data analytics team has created various market forecast models by employing the top-down approach i.e. starting with the large overall market and segmenting different areas and the bottom-up approach i.e. starting with population and epidemiology and rolling up based on spend, etc., estimating the size of the market, and distributing among the geographic and/or product segments.

The top-down approach is mainly used for new product forecasting and the bottom-up approach is used for demand estimation of any product for different countries summed up to form the total market. We are able to round off insights and build stronger forecasts because we always do both these methods and triangulate the final numbers.

The study on the market covers the analysis of the leading geographies such as Asia-Pacific, Africa, Europe, Middle East, North America, and  Latin America for the period of 2022 to 2030. The qualitative analysis covers the industry landscape and trends, market opportunities, competitive landscape, and policy and regulatory scenario, and the quantitative analysis covers different market estimates and forecasts.

Data Triangulation & Validation:

Data triangulation of various sources and results of the research are carried out by benchmarking with reliable sources such as industry statistics, statistical databases, and company-level averages, etc.

We make sure to finalize the numbers in alignment with the market research. Firstly, our internal experts ensure thorough validation and checking to ensure accurate and precise analysis and then validation is also done using a multiple-data analysis model. Two-level validation is done and entails the finalization of the report scope and the way of representation pattern.

 

 

Stage III: Interpretation and Presentation

Analysis & Interpretation: The information gathered is then analyzed and synthesized. The second series of interviews are done if necessary to check and validate. The future opportunities are analyzed by understanding product commercialization and many other factors. It also comprises the analysis of data discrepancies observed across various data sources. Information procured from secondary and primary results is then, interpreted by considering the following parameters: (a partial list)

  • Establishing market drivers and trends
  • Analyzing the regulatory landscape to understand future growth
  • Market Segment based analysis to obtain revenue/volume
  • ​Analyzing current needs and determining penetration to estimate the market

Insights: Our reports deliver actionable insights backed with supporting facts and figures to assist you in achieving exemplary growth. Our in-depth analyses are interspersed with relevant insights and statistics to offer an executive-level view of a given market. The description helps in correlating many minor factors affecting the market and their impact on the different segments within the market.

Data curated from the analysis and interpretation are drawn to portray all in one consolidated report.

Presentation & Reporting: The market research report is presented in different forms such as charts by using a scientific approach for easy understanding. Historic, current, and future analysis is provided for each market in terms of both value and volume. The size of the market is interpreted in the US Dollar value and the respective unit, based on the product, for volume consumption.

The foreign exchange rates are calculated on the respective dates and for the respective regions covered in the study.

To request a free sample copy of this report, please complete the form below.


We value your inquiry and offer free customization with every report to fulfil your exact research needs.

Lamba, Neopharma, and Bayer are the major players in the UAE cancer immunotherapy market.

The UAE cancer immunotherapy market is expected to grow from $563 Mn in 2022 to $1,049 Mn in 2030 with a CAGR of 8.1% for the forecasted year 2022-2030.

The UAE cancer immunotherapy market is segmented by type, application, and end user.


This report addresses

  • Intelligent insights to take informed business decisions
  • Qualitative, acute and result oriented market analysis
  • Market size and forecasts from 2022 to 2030
  • Opportunities for expansion and in-depth market analysis
  • Segmentation and regional revenue forecasts
  • Analysis of the market share and competitive landscape
  • Strategic Recommendations to chart future course of action
  • Comprehensive Market Research Report in PDF and PPT formats

Need more?

  • Ask our analyst how this study was put together to learn more
  • Discuss additional requirements as part of the free customisation
  • Add more countries or regions to the scope 
  • Get answers to specific business questions 
  • Develop the business case to launch the product
  • Find out how this report may influence your business revenue
Last updated on: 12 February 2024
Updated by: Dhruv Joshi

Related reports (by category)


Related reports (by geography)


subscribe to our newsletter
up